An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

Throughout the last three months, 11 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, ...

BioNTech (NASDAQ:BNTX) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on BioNTech (NASDAQ:BNTX) in the last three months. The table below summarizes their recent ratings ...

Deep-pocketed investors have adopted a bearish approach towards BioNTech (NASDAQ:BNTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

BioNTech SE will announce its financial results for the fourth quarter and full year of 2024 on March 10, 2025, followed by a conference call and webcast at 8:00 a.m. EDT. Interested parties can ...

BioNTech SE will announce its financial results for the first quarter of 2025 on May 5, 2025, and will hold a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss these results and ...

BioNTech SE will release its financial results for the second quarter of 2025 on August 4, 2025, and will hold a conference call and webcast that day at 8:00 a.m. EDT to discuss these results and ...

BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is ...

BioNTech will present preclinical data characterizing the mode of action of BNT327. BNT327 is an investigational next-generation bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A ...